# Call MVA2_3: essay=MVA2 stage=critique role=reviewer model=deepseek-ai/deepseek-v4.1-flash (nim)
time=2026-10-17T20:32:07 seconds=883.1 usage={} error=RuntimeError('deepseek-ai/deepseek-v4.1-flash failed: 504 ')

## SYSTEM

You are a senior translational geneticist and paediatric clinical pharmacologist reviewing a drug-repurposing hypothesis for a rare disease. Be critical and specific. Cite only papers you are confident exist, as PMID or DOI; if unsure, say 'citation needed' instead of inventing one. Do not give doses. This is a research review, not medical advice.

## PROMPT

# Review request: allele-aware repurposing of approved medicines for BUB1B mosaic variegated aneuploidy (MVA1)

Context (public knowledge only; no patient data is included here):
- MVA1 is caused by biallelic BUB1B variants. BUBR1 is a spindle-assembly-checkpoint pseudokinase; its kinase domain (aa 766-1050) is needed for conformational stability rather than catalysis (Suijkerbuijk et al., Dev Cell 2012, PMID 22698286). In patient cells, kinase-domain missense alleles (e.g. I909T, L1012P) make unstable, HSP90-dependent protein; truncating alleles make no protein (Suijkerbuijk et al., Cancer Res 2010, PMID 20516114).
- Genotype class under review: one nonsense allele upstream of the kinase domain (UGA stop, predicted to trigger nonsense-mediated decay) in trans with one missense allele inside the kinase domain C-lobe, ~10 residues from L1012P, predicted destabilising by sequence/structure models.
- Typical MVA1 clinical context (literature): embryonal tumours (rhabdomyosarcoma, Wilms), growth restriction, microcephaly, renal anomalies; children may be receiving or have received chemotherapy including vinca alkaloids.

Our ranked candidates (approved medicines only; research hypotheses for laboratory testing):
1. niacin (NAD+ precursor -> SIRT2 deacetylates and stabilises BUBR1; North 2014 PMID 24825348) - fits the missense allele only
2. arimoclomol (heat-shock-response co-inducer; licensed for Niemann-Pick C from age 2) - to raise steady-state level of the folding-defective missense protein
3. everolimus (low-dose mTORC1 dampening; muscle mTORC1 hyperactivity in BubR1 truncating-allele mice, Sieben 2020 PMID 31738183)
4. dasatinib (+quercetin) senolytic (p16+ cell clearance delays progeroid features in BubR1 hypomorphic mice, Baker 2011 PMID 22048312)
5. sodium phenylbutyrate (chemical chaperone)
6. sirolimus, 7. metformin, 8. hydroxychloroquine, 9. gentamicin (read-through of the UGA nonsense allele; cell-assay probe only), 10. ruxolitinib
Do-no-harm flags: tubulin binders, Aurora/PLK1/KIF11 inhibitors, HSP90 inhibitors (missense BUBR1 is an HSP90 client).

Please answer in this structure:
A. For each of the top 5: the single strongest scientific objection, and whether the ranking position is justified.
B. Up to 5 market-approved medicines we have missed that act on the BUBR1 protein-stability / proteostasis axis, the SAC/aneuploidy-tolerance axis, or the progeroid/senescence axis. For each: mechanism, the evidence (PMID/DOI only if certain), and the main paediatric safety concern.
C. Specific interactions or safety conflicts with concurrent paediatric rhabdomyosarcoma chemotherapy (vincristine, actinomycin D, cyclophosphamide, irinotecan) for any candidate.
D. The single most informative and cheapest first experiment in patient-derived cells.
Keep it under 900 words.


## RESPONSE


